Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common altitude sickness pill help treat sleep apnea?

NCT ID NCT04726982

Disease control Sponsor: University Hospital, Antwerp Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two doses (250 mg and 500 mg daily) of acetazolamide, a drug usually used for altitude sickness, in 91 adults with moderate to severe obstructive sleep apnea. The goal was to see if the drug could reduce breathing pauses during sleep by improving breathing control. Participants took the drug or a placebo for a period, and researchers measured changes in sleep apnea severity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Acetazolamide (Diamox)
What this could lead to
If successful, this could provide a new medication option for people with obstructive sleep apnea, reducing the need for CPAP machines.
What could go wrong
This is a small, early-phase trial with only 91 participants. The drug may cause side effects like tingling or electrolyte imbalances, and results may not apply to everyone with sleep apnea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

91 people

The number who actually took part.

Started

Apr 2021

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * AHI between 15 and 65 events/hour * BMI \< 35 kg/m² Exclusion Criteria: * Craniofacial anomalies * Central sleep apnea (defined as central AHI \> 25% of total AHI) * Contra-indications related to acetazolamide treatment * Hypersensitivity to sulphonamides or acetazolamide * Renal impairment, electrolyte imbalances, and/or adrenocortical insufficiency * Clinically significant metabolic, hepatic, and/or hematological disease * Chronic obstructive pulmonary disease * Closed-angle glaucoma * Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorders, heart failure, or any other unstable major medical condition. * Intake of drugs that substantially stimulate or depress respiration, including benzodiazepines, opioids, theophylline, and pseudoephedrine * Inadequately treated sleep disorders other than OSA that would confound functional sleep assessment * Inability of the patient to understand and/or comply to the study procedures * Active psychiatric disease (psychotic illness, major depression, anxiety attacks, alcohol or drug abuse) * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obstructive sleep apnea are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Acidosis obstructive sleep apnea syndrome Respiratory Aspiration sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obstructive sleep apnea

Contacts and locations

Locations

  • Antwerp University Hospital

    Edegem, Antwerp, 2650, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.